Recombinant Human Hla Class Ii Histocompatibility Antigen, Dp Beta 1 Chain (HLA-DPB1) Protein (His)

Name: Recombinant Human Hla Class Ii Histocompatibility Antigen, Dp Beta 1 Chain (HLA-DPB1) Protein (His)
Brand: Beta LifeScience
SKU: BLC-03550P
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Product Overview

Description	Recombinant Human Hla Class Ii Histocompatibility Antigen, Dp Beta 1 Chain (HLA-DPB1) Protein (His) is produced by our E.coli expression system. This is a protein fragment.
Purity	Greater than 90% as determined by SDS-PAGE.
Uniprotkb	P04440
Target Symbol	HLA-DPB1
Synonyms	beta1 domain MHC class II HLA DPB; class II histocompatibility antigen; DP(W4) beta chain; class II HLA beta chain; DP beta 1 chain; DP(W4) beta chain; DPB1; DPB1_HUMAN; HLA class II histocompatibility antigen; HLA class II histocompatibility antigen; DP beta 1 chain; HLA class II histocompatibility antigen; DP(W4) beta chain; HLA DP14-beta chain; HLA-DP; HLA-DP histocompatibility type; beta-1 subunit; HLA-DP1B; HLA-DPB; HLA-DPB1; major histocompatibility complex class II antigen beta chain; major histocompatibility complex; class II; DP beta 1; MHC class II antigen beta chain; MHC class II antigen DP beta 1 chain; MHC class II antigen DPB1; MHC class II antigen DPbeta1; MHC class II HLA-DP-beta-1; MHC class II HLA-DRB1; MHC HLA DPB1
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-6His
Target Protein Sequence	RATPENYLFQGRQECYAFNGTQRFLERYIYNREEFARFDSDVGEFRAVTELGRPAAEYWNSQKDILEEKRAVPDRMCRHNYELGGPMTLQRRVQPRVNVSPSKKGPLQHHNLLVCHVTDFYPGSIQVRWFLNGQEETAGVVSTNLIRNGDWTFQILVMLEMTPQQGDVYTCQVEHTSLDSPVTVEWKAQSDSAR
Expression Range	30-223aa
Protein Length	Partial
Mol. Weight	26.8kDa
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.
Subcellular Location	Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass type I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation.
Protein Families	MHC class II family
Database References	HGNC: 4940 OMIM: 142858 KEGG: hsa:3115 STRING: 9606.ENSP00000408146 UniGene: Hs.485130

Gene Functions References

Data suggest that HLA-DP molecules with beta-chains encoding Gly84 (DP(84Gly)) uses both class I and II antigen-processing pathways to present peptides derived from intracellular and extracellular sources. PMID: 28489076
HLA-DP polymorphisms (rs3077 and rs9277535) were associated with Systemic lupus erythematosus susceptibility in a Chinese population PMID: 28094303
High frequency expression of DPB1*0401 and *0601 are significantly associated with susceptibility to rheumatoid arthritis, it may be a risk factor for occurrence of rheumatoid arthritis. Low frequency expression of DPB1*0101, *0402 and *0501 may be negatively associated with rheumatoid arthritis, it may be a protective factor for occurrence of rheumatoid arthritis. PMID: 29425827
The rs3117242 of HLA-DPB1 could be considered a genetic risk factor for granulomatosis with polyangiitis in Chinese Han people. PMID: 26014903
HLA-DPB1*05:01 gene was associated with the geographical region of PV and the BTNL2 gene was significantly associated with family history and age of onset of PV. In conclusion, the HLA-DPB1*05:01 and BTNL2 genes might be responsible for the complicacy of clinical features. PMID: 28581127
In this single-center study, HLA-DPB1 matching influenced outcomes of patients undergoing ASCT for hematologic malignancy. PMID: 28632323
HLA-DPB1*15:01 allele was more frequent in the spontaneous seroconverted control group compared to Chronic hepatitis B Turkish patients. PMID: 29560661
Genotyping and expression analysis in HLA class II gene revealed that two single nucleotide polymorphisms of HLA-DPB1 (rs2071025 and rs3116996) were significantly correlated to RNA expression and progression of hepatitis C virus-related liver diseases. PMID: 28332201
Amino acid changes in the allergen-binding pocket of HLA-DPbeta1 are likely to influence pollinosis/sensitization to the allergenic peptide of JC pollen and determine the pollinosis risk for each individual exposed to JC pollen. PMID: 28460831
The results showed that rs9277535 HLA-DPB1 allele frequency is associated with chronic hepatitis B infection in the Turkish patients. PMID: 28119119
report contributes to emerging data showing clinical significance of the HLA-DP region genetic markers beyond structural matching of DPB1 alleles. PMID: 27595289
The HLA-DP rs9277535 variant genotypes were directly associated with hepatitis B virus persistence compared to healthy controls. PMID: 27291710
No statistically significant association was found between rs9277535 SNP and chronic hepatitis B. PMID: 28613373
Two new signals were observed at genome-wide significance (P < 5 x 10-8), namely, rs7216064 (17q24.3, BPTF), for overall lung adenocarcinoma risk, and rs3817963 (6p21.3, BTNL2) which is specific to cases with EGFR mutations. In further sub-analyses by EGFR status, rs9387478 (ROS1/DCBLD1) and rs2179920 (HLA-DPB1) showed stronger estimated associations in EGFR-positive compared to EGFR-negative cases PMID: 28025329
we show strong immunogenicity of HLA-DPB1 mismatch alleles in CD45RA-selected CD4 T cells of stem-cell donors and introduce a novel strategy to reliably generate HLA-DPB1-specific CD4 CTL that might be powerful cellular therapeutics in relapsed or refractory AML after HSCT. PMID: 27479183
There was no increased risk of rheumatoid arthritis in mothers of children with phenylalanine at position 9 of DPB1. PMID: 28391248
rs141530233 and rs1042169 at the HLA-DPB1 locus are associated with ANCA-associated vasculitis risk. PMID: 28029757
Seven nonconservative AA substitutions in peptide-binding positions had a significantly stronger impact on DeltaFD compared with 5 others (P = .0025), demonstrating qualitative differences in the relative impact of AA polymorphism in HLA-DPB1. PMID: 27162243
Study showed that HLA-DQ (rs7453920) was associated with prognosis of liver transplant recipients. The A allele of rs7453920 served as a protective factor in liver function recovery. HLA-DP (rs3077 and rs9277535) did not show any correlation with the hepatitis B virus infection and prognosis. PMID: 28640108
two dermatomyositis susceptibility loci at 7q34 and 10q24.2 PMID: 27153935
this study shows that HLA-DP gene polymorphisms are associated with ankylosing spondylitis in Southwest China PMID: 27394003
DRB1*13:02 (P = 0.0011, Pc = 0.0319, odds ratio [OR] 0.46, 95% confidence interval [CI] 0.29-0.73), DRB1*14:06 (P = 6.60X10-5, Pc = 0.0020, OR 0.05, 95%CI 0.01-0.41), DQB1*03:01 (P = 0.0009, Pc = 0.0150, OR 0.56, 95%CI 0.40-0.79), and DPB1*02:01 (P = 5.16X10-6, Pc = 8.77X10-5, OR 0.52, 95%CI 0.39-0.69) were protectively associated with Systemic Sclerosis in Japanese. PMID: 27116456
The HLA-DPB1*04:01:01G allele was significantly more frequent among women diagnosed with severe preeclampsia/eclampsia compared with controls. PMID: 27121092
the HLA-DP/DQ clusters contribute independently to HBV infection, and the 3'-UTR region of HLA-DPB1 represents an important functional region involved in HBV infection PMID: 26197724
Significant associations between chronic hepatitis B infection and five DPB1 alleles (two susceptibility alleles, DPB1(*) 05:01 and (*) 09:01, and three protective alleles, DPB1(*) 02:01, (*) 04:01, and (*) 04:02) were confirmed in Japanese individuals. PMID: 26449183
The observed positive association between integrated HIV-1 DNA load and frequency of CD8(+)DR/DP/DQ(+) cells indicates that a close correlation between HIV persistence and immune activation continues during consistently suppressive therapy. PMID: 26498496
Our results further confirm that genetic variants in the HLA-DP locus are strongly associated with reduced HBV infection and increased the likelihood of spontaneous viral clearance. PMID: 26462556
Thyroid autoimmunity is highly prevalent in type 1 diabetes mellitus patients and the risk is modulated by HLA-DRB1 and HLA-DPB1 loci. PMID: 26405068
DQB1*06 and DPB1*13 have roles in modulating vaccine-induced antibody responses to affect HIV-1 acquisition PMID: 26180102
rs9277535 in HLA-DPB1 is a significantly associated SNP associated with chronic hepatitis B virus infection and viral clearance. PMID: 24846544
Cellular misfolded proteins rescued from degradation by MHC class II molecules seem to be involved in autoimmune diseases as a target for autoantibodies. (review) PMID: 26915265
findings indicate the HLA-DPB1*13:01 and +550 A alleles are significantly associated with cervical squamous cell carcinoma (CSCC) risk in Taiwanese women; in addition, significant increase in CSCC risk was observed for HLA-DPB1*13:01-G and DPB1*02:01-A haplotypes PMID: 26031576
There was a significant linkage disequilibrium between these HLA-DP candidate SNPs and HLA-DPB1 protective alleles PMID: 25389088
This implies the potential of rs3128965 of HLA-DPB1 as a genetic marker for diagnosis and prediction of the AERD phenotype. PMID: 25536158
HLA-DPB1*04:01 may reduce the risk of tissue transglutaminase autoantibodies, an early marker of celiac disease, among DR3-DQ2 children, confirming that additional variants in the HLA region influence the risk for celiac disease autoimmunity. PMID: 26010309
Among recipients of HLA-DPB1-mismatched transplants from donors with the low-expression allele, recipients with the high-expression allele had a high risk of GVHD. PMID: 26267621
Results identified new susceptibility variants to narcolepsy in HLA-DPB1 and HLA-DQB1 loci in Japanese patients. PMID: 25256355
The affinities of peptides for Beryllium loaded HLA-DP2 were found to depend of their amino acid composition and the peptides carrying acidic group at positions 4 and 7 are among the strongest binders. PMID: 25369028
Polymorphisms in HLA-DPB1 are strongly associated with interindividual differences in neutralizing antibody levels to rubella vaccination. PMID: 25293367
This is the first report of the association between early Crohn's disease and the HLA DRB1*501 single nucleotide polymorphisms. PMID: 25664710
No increase in sarcoidosis was seen with either Glu69 or beryllium exposure. In Glu69 positive men with exposure >/=10 years, the trend towards increasing rate of COPD was reversed; a significant interaction of duration of exposure and Glu69 was detected. PMID: 25305207
Data indicate that thirty eight HLA-DPB1 alleles were found in the systemic scleroderma cohort. PMID: 24498086
HLA-DPB1 alleles influence the kinetics of anti-hepatitis B antibodies in hepatitis B booster recipients. PMID: 24285177
Data indicate that HLA-DP2 transgenic mice developed a beryllium-specific adaptive immune response composed of CD4+ T cells. PMID: 24912188
Data indicate five members of of DPbeta chains containing Lys-69 and GGPM 84-87, which assemble with DRalpha. PMID: 24214983
Our results demonstrated that the rs3077 and rs9277535 HLA-DP polymorphisms reduced hepatitis B virus infection and increased the likelihood of spontaneous viral clearance in some Asian populations. PMID: 23601003
Studied three HLA-DP and IL28B SNPs of CHB patients with and without spontaneous HBsAg seroclearance. Haplotype analysis of HLA-DP polymorphisms showed association with HBsAg seroclearance. PMID: 23449268
HLA-DRB1*04:01 and HLA-DPB1*04:01 alleles were detected at higher frequencies in influenza-seroprotected compared with non-seroprotected individuals. PMID: 23951151
The conditional logistic regression tests showed that DPB1*04:01 is independently associated with non-obstructive azoospermia(NOA), confirming the involvement of the HLA region in the etiology of NOA in Japanese patients. PMID: 23934009
We identified the SEMA6A and HLA-DP loci as significant contributors to risk for granulomatosis with polyangiitis, with the HLA-DPB1*04 allele almost completely accounting for the MHC association PMID: 23740775

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.